Inventiva (NASDAQ:IVA) Coverage Initiated by Analysts at Truist Financial

Truist Financial assumed coverage on shares of Inventiva (NASDAQ:IVA) in a report released on Thursday, Marketbeat Ratings reports. The firm issued a buy rating and a $13.00 price target on the stock.

Several other research analysts also recently weighed in on the stock. Leerink Partners assumed coverage on shares of Inventiva in a research note on Monday, January 12th. They issued an “outperform” rating and a $12.00 target price for the company. HC Wainwright set a $24.00 target price on Inventiva and gave the stock a “buy” rating in a research report on Wednesday, January 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a report on Thursday, January 22nd. UBS Group began coverage on Inventiva in a research note on Wednesday, January 7th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Barclays assumed coverage on shares of Inventiva in a report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Inventiva currently has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Trading Up 1.3%

IVA stock opened at $6.04 on Thursday. Inventiva has a 1 year low of $2.70 and a 1 year high of $7.98. The stock has a 50-day simple moving average of $6.28 and a 200-day simple moving average of $5.36.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Paradigm Biocapital Advisors LP bought a new position in Inventiva in the 4th quarter worth approximately $18,600,000. ADAR1 Capital Management LLC acquired a new stake in Inventiva in the fourth quarter worth approximately $12,601,000. Millennium Management LLC lifted its holdings in Inventiva by 2,267.7% in the 4th quarter. Millennium Management LLC now owns 2,652,570 shares of the company’s stock valued at $12,334,000 after acquiring an additional 2,540,540 shares during the last quarter. UBS Group AG lifted its holdings in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock valued at $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. Finally, SymBiosis Capital Partners LLC acquired a new position in Inventiva in the 4th quarter worth approximately $12,090,000. 19.06% of the stock is owned by institutional investors and hedge funds.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.